Make an enquiry
Refer a patient
Patient Portal
HCP Logout

We noticed you are on our AU page. Want to switch regions? Choose from the options:

UK
ES
Find a centre
Find a doctor
Make an enquiry
Refer a patient

We noticed you are on our AU page. Want to switch regions? Choose from the options:

UK
ES
Find a centre
Find a doctor
2024-02-13T00:00:00.000+11:00
Ongoing

Beigene BGB-11417-203

Beigene BGB-11417-203
Waldenström’s Macroglobulinemia

An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of BCL2 Inhibitor BGB-11417 in Patients With Relapsed/Refractory Waldenström’s Macroglobulinemia

An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of BCL2 Inhibitor BGB-11417 in Patients With Relapsed/Refractory Waldenström’s Macroglobulinemia

Trial overview

Clinical Area

Haematology

Disease / Condition

Waldenström’s Macroglobulinemia

Phase

II

Trial registration

Number: NCT05952037

Further information

Please click here for more information

GenesisCare Location(s)

GenesisCare North Shore 

GenesisCare North Shore  :::
Principal Investigator(s)

Dr David Kilman

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.